James G. Cullem

Portrait
James G. Cullem, Chief Executive Officer

James G. Cullem has been the Chief Executive Officer (interim) of Allarity Therapeutics, Inc. since June 2022, and has been a part of the Company’s senior management team since 2014. He most recently served as the Company’s Chief Business Officer, and previously served as its Senior Vice President, Corporate Development (including the Company' predecessors, Allarity Therapeutics A/S and Oncology Venture A/S). He brings 20+ years of diverse experience in life sciences organizational management, business development & licensing, intellectual property & technology transfer/commercialization, alliance management, and strategic planning as a member of executive teams. During his tenure, Mr. Cullem has been responsible for the identification and acquisition of most of our lead clinical oncology assets, including big pharma therapeutics dovitinib (from Novartis) and stenoparib (from Eisai). He leads the company’s global business and strategic development efforts, and played an instrumental role in the Company’s restructuring and re-focus of its clinical pipeline in 2019 and its migration to the U.S. Nasdaq in 2021. Mr. Cullem has experience in designing and negotiating a broad span of life science deals, has founded and led several early-stage biotech companies, and is a catalyst for businesses taking the next step in the fields of precision medicine and predictive/companion diagnostics, novel drug targets, proteomics and genomics, and clinical-stage cancer therapeutic development. Prior to Allarity, he served as part of the executive management teams of Enzymatics, Inc. and Cell Signaling Technology, Inc. and started his scientific career conducting bench research in virology and diagnostics at Chiron Corporation and the J. David Gladstone Institutes.He holds a B.S. degree in Biochemistry from The University of California at Davis, a Juris Doctorate (JD) degree from The University of New Hampshire Franklin Pierce School of Law, specializing in patent & I.P. law, and is a registered patent attorney before the United States Patent & Trademark Office.